STOCK TITAN

[SCHEDULE 13G/A] DarioHealth Corp. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

DarioHealth Corp. reporting persons Nantahala Capital Management, LLC and principals Wilmot B. Harkey and Daniel Mack disclose beneficial ownership of 4,690,019 shares, representing 9.99% of the outstanding common stock as of June 30, 2025. The disclosed position includes 2,997,716 shares that may be acquired within 60 days through the exercise of warrants, and all voting and dispositive power is reported as shared rather than sole. Nantahala identifies two advised funds with rights to receive proceeds or dividends from more than 5% of the shares reported.

DarioHealth Corp. i soggetti segnalanti Nantahala Capital Management, LLC e i dirigenti Wilmot B. Harkey e Daniel Mack comunicano la proprietà effettiva di 4.690.019 azioni, pari al 9,99% del capitale sociale ordinario in circolazione al 30 giugno 2025. La posizione dichiarata comprende 2.997.716 azioni che possono essere acquisiste entro 60 giorni mediante l'esercizio di warrant, e tutti i diritti di voto e dispositivi sono indicati come condivisi anziché esclusivi. Nantahala segnala inoltre due fondi consulenti con diritto a ricevere proventi o dividendi su oltre il 5% delle azioni segnalate.

DarioHealth Corp. los informantes Nantahala Capital Management, LLC y los principales Wilmot B. Harkey y Daniel Mack revelan la propiedad beneficiaria de 4.690.019 acciones, que representan el 9,99% del capital social ordinario en circulación al 30 de junio de 2025. La posición declarada incluye 2.997.716 acciones que pueden adquirirse dentro de 60 días mediante el ejercicio de warrants, y todos los poderes de voto y disposición se informan como compartidos en lugar de exclusivos. Nantahala identifica además dos fondos asesorados con derecho a recibir ingresos o dividendos sobre más del 5% de las acciones reportadas.

DarioHealth Corp.의 보고자 Nantahala Capital Management, LLC와 주요인물 Wilmot B. Harkey 및 Daniel Mack는 2025년 6월 30일9.99%에 해당하는 4,690,019주에 대한 실질적 소유를 공시합니다. 공시된 보유에는 워런트 행사로 60일 이내에 취득할 수 있는 2,997,716주가 포함되며, 모든 의결권 및 처분 권한은 단독이 아닌 공동으로 보고됩니다. Nantahala는 또한 보고된 주식의 5% 초과에 대해 수익이나 배당을 받을 권리가 있는 두 개의 자문 펀드를 식별합니다.

DarioHealth Corp. les personnes déclarante Nantahala Capital Management, LLC et les dirigeants Wilmot B. Harkey et Daniel Mack déclarent une détention bénéficiaire de 4 690 019 actions, représentant 9,99% des actions ordinaires en circulation au 30 juin 2025. La position divulguée inclut 2 997 716 actions pouvant être acquises dans les 60 jours par l'exercice de warrants, et tous les pouvoirs de vote et de disposition sont indiqués comme partagés plutôt que exclusifs. Nantahala identifie également deux fonds conseillés ayant le droit de recevoir des produits ou dividendes sur plus de 5% des actions déclarées.

DarioHealth Corp. meldende Personen Nantahala Capital Management, LLC und die Verantwortlichen Wilmot B. Harkey und Daniel Mack geben den wirtschaftlichen Besitz von 4.690.019 Aktien bekannt, was 9,99% des zum 30. Juni 2025 ausstehenden Stammkapitals entspricht. Die gemeldete Position umfasst 2.997.716 Aktien, die innerhalb von 60 Tagen durch Ausübung von Warrants erworben werden können, und sämtliche Stimm- und Verfügungsrechte werden als geteilt statt als allein angegeben. Nantahala benennt zudem zwei beratenen Fonds mit dem Recht, Erträge oder Dividenden aus mehr als 5% der gemeldeten Aktien zu erhalten.

Positive
  • Significant disclosed stake: 4,690,019 shares reported, demonstrating substantial economic interest in DRIO
  • Transparency on exercisable warrants: Filing explicitly states 2,997,716 shares may be acquired within 60 days
  • Identification of economic beneficiaries: Specific funds advised by Nantahala are named as having rights to proceeds or dividends
Negative
  • Position just below 10%: Reported ownership is 9.99%, which avoids certain regulatory thresholds that apply at or above 10%
  • All power is shared: No sole voting or dispositive power reported, limiting clarity on who would act unilaterally

Insights

TL;DR: Nantahala and two principals report a near-10% shared stake, including exercisable warrants that could increase effective ownership.

The Schedule 13G/A shows a meaningful but sub-10% position in DRIO of 4,690,019 shares (9.99%), including 2,997,716 warrant-based shares exercisable within 60 days. Shared voting and dispositive power indicates control is exercised collectively through the adviser and named principals. The position is large enough to be material to investors but remains below 10%, avoiding certain reporting triggers. Identification of specific advised funds clarifies who economically benefits from the holdings.

TL;DR: Reporting persons disclose collective influence but not sole control; governance impact depends on coordination among stakeholders.

The filing classifies Nantahala as an investment adviser and Messrs. Harkey and Mack as control persons regarding the shares held by funds under Nantahala's control. All reported voting and dispositive power is shared, which suggests decisions are made through the adviser/fund structure rather than by a single individual. The disclosure that certain advised funds have the right to receive proceeds clarifies economic beneficiaries, which is important for assessing potential governance actions.

DarioHealth Corp. i soggetti segnalanti Nantahala Capital Management, LLC e i dirigenti Wilmot B. Harkey e Daniel Mack comunicano la proprietà effettiva di 4.690.019 azioni, pari al 9,99% del capitale sociale ordinario in circolazione al 30 giugno 2025. La posizione dichiarata comprende 2.997.716 azioni che possono essere acquisiste entro 60 giorni mediante l'esercizio di warrant, e tutti i diritti di voto e dispositivi sono indicati come condivisi anziché esclusivi. Nantahala segnala inoltre due fondi consulenti con diritto a ricevere proventi o dividendi su oltre il 5% delle azioni segnalate.

DarioHealth Corp. los informantes Nantahala Capital Management, LLC y los principales Wilmot B. Harkey y Daniel Mack revelan la propiedad beneficiaria de 4.690.019 acciones, que representan el 9,99% del capital social ordinario en circulación al 30 de junio de 2025. La posición declarada incluye 2.997.716 acciones que pueden adquirirse dentro de 60 días mediante el ejercicio de warrants, y todos los poderes de voto y disposición se informan como compartidos en lugar de exclusivos. Nantahala identifica además dos fondos asesorados con derecho a recibir ingresos o dividendos sobre más del 5% de las acciones reportadas.

DarioHealth Corp.의 보고자 Nantahala Capital Management, LLC와 주요인물 Wilmot B. Harkey 및 Daniel Mack는 2025년 6월 30일9.99%에 해당하는 4,690,019주에 대한 실질적 소유를 공시합니다. 공시된 보유에는 워런트 행사로 60일 이내에 취득할 수 있는 2,997,716주가 포함되며, 모든 의결권 및 처분 권한은 단독이 아닌 공동으로 보고됩니다. Nantahala는 또한 보고된 주식의 5% 초과에 대해 수익이나 배당을 받을 권리가 있는 두 개의 자문 펀드를 식별합니다.

DarioHealth Corp. les personnes déclarante Nantahala Capital Management, LLC et les dirigeants Wilmot B. Harkey et Daniel Mack déclarent une détention bénéficiaire de 4 690 019 actions, représentant 9,99% des actions ordinaires en circulation au 30 juin 2025. La position divulguée inclut 2 997 716 actions pouvant être acquises dans les 60 jours par l'exercice de warrants, et tous les pouvoirs de vote et de disposition sont indiqués comme partagés plutôt que exclusifs. Nantahala identifie également deux fonds conseillés ayant le droit de recevoir des produits ou dividendes sur plus de 5% des actions déclarées.

DarioHealth Corp. meldende Personen Nantahala Capital Management, LLC und die Verantwortlichen Wilmot B. Harkey und Daniel Mack geben den wirtschaftlichen Besitz von 4.690.019 Aktien bekannt, was 9,99% des zum 30. Juni 2025 ausstehenden Stammkapitals entspricht. Die gemeldete Position umfasst 2.997.716 Aktien, die innerhalb von 60 Tagen durch Ausübung von Warrants erworben werden können, und sämtliche Stimm- und Verfügungsrechte werden als geteilt statt als allein angegeben. Nantahala benennt zudem zwei beratenen Fonds mit dem Recht, Erträge oder Dividenden aus mehr als 5% der gemeldeten Aktien zu erhalten.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025

FAQ

How many DarioHealth (DRIO) shares does Nantahala report owning?

The filing reports 4,690,019 shares beneficially owned by Nantahala and the named principals.

What percentage of DRIO does the reported position represent?

The reported position represents 9.99% of DarioHealth's outstanding common stock as of June 30, 2025.

Does the filing include shares that can be acquired soon?

Yes. The 4,690,019 total includes 2,997,716 shares that may be acquired within 60 days through the exercise of warrants.

Do the reporting persons have sole voting or dispositive power over the shares?

No. The filing reports 0 shares with sole voting or dispositive power and 4,690,019 shares with shared voting and dispositive power.

Which funds are identified as economic beneficiaries of the reported shares?

The filing names Nantahala Capital Partners Limited Partnership and Blackwell Partners LLC - Series A as funds advised by Nantahala with rights to proceeds or dividends.
Dariohealth Corp

NASDAQ:DRIO

DRIO Rankings

DRIO Latest News

DRIO Latest SEC Filings

DRIO Stock Data

19.67M
36.71M
19.24%
15.51%
6.68%
Health Information Services
Surgical & Medical Instruments & Apparatus
Link
United States
NEW YORK